CTOs on the Move

Center For Disease Detection

www.cddmedical.com

 
Center For Disease Detection, LLC is a San Antonio, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.cddmedical.com
  • 3370 Nacogdoches Rd Ste 100
    San Antonio, TX USA 78217
  • Phone: 210.590.3033

Executives

Name Title Contact Details

Similar Companies

Kainos Dental Lab

Kainos Dental Lab is a Walnut Creek, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Springborn Laboratories

Springborn Laboratories is a Wareham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Greenwood Genetic Center

Since 1974, the Greenwood Genetic Center has been a leader in the delivery of genetic services, committed to: Diagnosing genetic conditions Counseling individuals and families Researching the causes of birth defects and genetic diseases Educating

Ikonisys

Ikonisys is a New Haven, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Jounce Therapeutics

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within the human tumor microenvironment to prioritize targets, and then identifies related biomarkers designed to match the right immunotherapy to the right patient. Jounce is developing two clinical-stage programs as well as advancing and building out its broad and wholly-owned discovery pipeline of immuno-oncology targets, including those expressed on T-regulatory cells, macrophages and stromal cells. Jounce`s lead product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS and is currently being assessed in a Phase 2 clinical trial. JTX-4014 is a PD-1 inhibitor intended for use in combination with future pipeline products, and Jounce has completed enrollment in the JTX-4014 Phase 1 clinical trial. In addition, Jounce has exclusively licensed worldwide rights to JTX-8064, a LILRB2 receptor antagonist, to Celgene. For more information, please visit www.jouncetx.com. We have many career opportunities at Jounce and are looking for exceptional individuals who share our passion and perseverance for developing highly durable cancer immunotherapies that can dramatically impact and improve patients` lives.